ArticleTH open : companion journal to thrombosis and haemostasis2026
Edoxaban versus Apixaban Outcomes Differences in 8,444 Patients with Atrial Fibrillation from Italy: A Real-World Use Comparison.
Article in TH open : companion journal to thrombosis and haemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Based on efficacy and safety data from randomized controlled trials (RCTs) and real-world studies, direct oral anticoagulants are recommended for thromboembolism prevention in patients with atrial fibrillation (AF). However, no RCTs have compared edoxaban with apixaban. Objectives: This study aimed to retrospectively compare clinical outcomes for patients with AF in Italy (overall and by age group) who received edoxaban versus apixaban. Methods: Adult patients with AF who newly initiated an edoxaban or apixaban prescription between January 2016 and December 2021 were identified from the Italian IQVIA Results: Among 8,444 identified patients, 37.8% ( Conclusion: IS/SE risk was significantly lower for edoxaban versus apixaban, without an increased MB risk among patients with AF overall and those aged ≥80 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.